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Oral cancer, represented mainly by oral squamous cell carcinoma (OSCC), is the eighth most common type of human
cancer worldwide. The number of new OSCC cases is increasing worldwide, especially in the low-income countries, and the
prognosis remains poor in spite of recent advances in the diagnostic and therapeutic modalities. MicroRNAs (miRNAs), 18–25
nucleotides long noncoding RNA molecules, have recently gained significant attention as potential regulators and biomarkers for
carcinogenesis. Recent data show that several miRNAs are deregulated in OSCC, and they have either a tumor suppressive or an
oncogenic role in oral carcinogenesis. This review summarizes current knowledge on the role of miRNAs as tumor promotors or
tumor suppressors in OSCC development and discusses their potential value as diagnostic and prognostic markers in OSCC.
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) consists
of a heterogeneous group of malignancies arising from oral
cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and
salivary glands. Oral cancer, represented mainly by oral
squamous cell carcinoma (OSCC), is the most common
type of HNSCC. OSCC is the eighth most common cancer
worldwide accounting for more than 300,000 new cases and
145,000 deaths in 2012 [1]. Usually, OSCC detection depends
on the clinical examination of oral cavity, followed by a biopsy
for histological analysis. However, despite the easy access
for visual examination, OSCC is often detected at advanced
stages leading to severely reduced patient survival. In spite of
the recent advances in diagnosis and treatment modalities,
less than 50% of OSCC patients survive for 5 years [2]. Late
diagnosis, regional lymph node metastasis, and recurrences
are the major causes related to the poor prognosis and
reduced survival for OSCC patients [3, 4]. Thus, reliable
molecular markers that can (i) provide earlier and more
precise OSCC diagnosis, (ii) predict prognosis, and (ii) assign
patients to the best-targeted treatment available are urgently
needed.
For almost three to four decades, changes in protein
coding tumor suppressor genes and/or oncogenes have been
thought to be the main drivers of tumor development [5,
6]. However, the recent discovery of thousands of genes
that transcribe noncoding RNAs (including miRNAs) makes
it obvious that cancer biology is even more complex than
initially expected. Several layers of molecular regulators
(e.g., mRNA, miRNA, and protein) are involved in the
development and maintenance of cancerous phenotypes.
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Figure 1: Schematic illustration demonstrating biogenesis and function of miRNA. miRNA genes are transcribed into primary miRNA (pri-
miRNA) by RNA polymerase III.These miRNAs are further converted into second precursors (pre-miRNA) by Drosha and are exported into
cytoplasm by Exportin 5. Additional processing by Dicer produces miRNA:miRNA∗ duplex. Only one strand of miRNA:miRNA∗ duplex is
preferentially assembled into the RNA-induced silencing complex (RISC). RISC acts on target mRNA(s) and leads to either translational
repression or mRNA cleavage. Suppression of tumor suppressive genes and/or activation of oncogenes by miRNA lead to excessive cell
proliferation and survival, increased antiapoptosis, and enhanced invasive and metastatic potential of oral keratinocytes, resulting into
invasive cancerous growth.
Among them, miRNAs, 18–25 nucleotides long, noncod-
ing RNA molecules [7–9], have recently gained significant
attention as potential regulators and biomarkers for human
carcinogenesis. At the molecular level, miRNA binds to
3󸀠-untranslated region (3󸀠-UTR) of target mRNA(s) and
suppresses its expression by either translational repression or
mRNA cleavage [10] (Figure 1). A single miRNA can regulate
expression and/or function of hundreds of targetmRNAs and
proteins and regulates several biological processes (e.g., cell
proliferation, differentiation,migration, apoptosis, and signal
transduction) important for cancer development [8, 11–13]
(Figure 1).
Many recent studies have shown deregulated expression
of miRNAs in OSCC and OSCC-derived cell-lines compared
to their normal counterparts, indicating their potential role in
oral cancer development. Accordingly, several miRNAs have
been shown to function either as tumor suppressors or as
tumor promoters in OSCCs (reviewed in [14, 15]). In addition
to their key biological functions in OSCC tumorigenesis,
expression levels of several of miRNAs have been shown to
correlate with clinicopathological variables [16] and to have a
diagnostic and prognostic value in OSCC [15, 17]. For these
reasons, miRNA has been a hot topic in cancer research for
the last few years and several studies about miRNAs in OSCC
have been published recently, as summarized in Table 1. The
current review aims to highlight the oncogenic and tumor
suppressive roles of miRNAs in OSCC development and
discusses their potential value as diagnostic and prognostic
markers for OSCC management.
2. Methods
Literature search was performed by using the PubMed
database. Following key words were used for the litera-
ture search: “oral cancer and miRNA,” “oral cancer and
microRNA,” “oral squamous cell carcinoma andmiRNA,” and
“oral squamous cell carcinoma and microRNA.” Exclusion
criteria were articles not related to OSCC/HNSCC and/or
miRNA, purely descriptive articles, articles lacking clinical
pathological correlation, and/or articles for which full texts
were not available in English. Only clinically relevant articles
published within April 2015 were included in this review.
Additionally, individual articles retrieved manually from the
reference list of the relevant papers were also included.
3. miRNAs as Oncogenes in OSCC
A number of miRNAs have been shown to be upregulated
in OSCC and to function as oncogenes. A well-studied
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Table 1: Summary of miRNAs and associated signal pathways/target genes in OSCC/HNSCC.
miRNA Up/downregulation Target genes/associated pathways Ref.
miR-21 Up
PDCD4 [23]
TPMI [16]
RECK [26]
CLU [22]
DKK2-Wnt/𝛽-catenin [18]
Smad7-TGF𝛽1 [27]
HA/CD44-Nanog/Stat3-PDCD4, IAPs [24]
miR-31 Up FIH-HIF-EVGF [28]
miR-31∗ Up FGF3 [29]
RhoA [32]
miR-134 Up WWOX [36]
miR-146a Up IRK1, TRAF6, and NUMB [33]
miR-155 Up CDC73 [39]
miR-7 Up RECK [26]
IGF1R-Akt [45]
miR-9 Down CXCR4-Wnt/𝛽-catenin [50]
miR-17/20a Down ITG𝛽8 [60]
miR-29a Down MMP2 [57]
miR-34 Down E2F3, survivin, and VEGF [64]
SIRT6 [89]
miR-99a Down IGF1R [46]
miR-124 Down ITGB1 [58]
miR-125b Down ICAM2 [65]
miR-138 Down
FOSL1 [52]
VIM, ZEB2, EZH2 [53]
RhoC, and RoCK2 [54]
miR-140-5p Down ADAM10, ERBB4, PAX6, and LAMC1 [90]
miR-145 Down c-Myc, Cdk6 [67]
miR-181a Down K-ras [91]
Twist1 [56]
miR-205 Down IL-24, caspase-3/-7, [92]
and Axin-2 [93]
miR-218 Down mTOR-Rictor-Akt [48]
miR-320 Down HIF-1𝛼-NRP1-VEGF [41]
miR-357 Down CIP2A-MYC [61]
AEG-1/MTDH [62]
miR-419-5p Down GIT1 [59]
EGFR-ERK1/2-MMP2/9
miR-483-3p — API5, BRIC5, and RAN [94]
miR-196a Up MAMDC2 [95]
miR-26a/b Down TMEM184B [96]
miRNA, the miR-21, has been shown to be overexpressed
and to regulate several biological functions in OSCC [16,
18–20]. Overexpression of miR-21 has also been observed
in oral premalignant lesions (oral leukoplakia) compared
to normal oral mucosa, indicating that alteration in miR-
21 could be an earlier event in OSCC progression [21]. A
number of in vitro and in vivo experimental data have demon-
strated an oncogenic role of miR-21 in OSCC by promoting
cell proliferation [22], invasion [18, 23], antiapoptosis [16],
and chemoresistance [24]. These oncogenic functions were
shown to be regulated by miR-21-mediated downregulation
of several established tumor suppressor molecules, includ-
ing PTEN [25], programmed cell death 4 (PDCD4) [23],
tropomyosin [16], reversion-inducing cysteine-rich protein
with kazal motifs (RECK) [26], and dickkopf 2 (DKK2) [18].
In addition to the functional roles in OSCC cells, a growing
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body of evidence suggests that miR-21 might be important
in the regulation of carcinoma associated fibroblasts (CAFs)
induction and their activity [20, 27]. miR-21 was shown to
be predominately localized in OSCC stroma and colocalized
with 𝛼-smooth muscle actin positive CAFs. Additionally,
higher stromal expression ofmiR-21 was associatedwith poor
prognosis in OSCC [20].
miR-31 and its passenger strand miRNA (miR-31∗) have
been shown to be upregulated in oral leukoplakia (OLP) and
OSCC and to have an oncogenic role in OSCC tumorigenesis
[28–31]. Liu et al. demonstrated that ectopic expression
of miR-31 repressed its target factor-inhibiting hypoxia-
inducible factor (FIH) expression to activate hypoxia-
inducible factor (HIF) under normoxic conditions, both
in vitro and in vivo. Additionally, miR-31-FIH-HIF-VEGF
regulatory cascade was found to affect several biological
processes such as cell proliferation, migration, and epithelial-
mesenchymal transition (EMT) in OSCC cells [28]. More-
over, miR-31 was shown to collaborate with human telom-
erase reverse transcriptase (hTERT) to immortalize normal
oral keratinocytes (NOKs), indicating that itmight contribute
to early stage oral carcinogenesis [31]. Similarly, miR-31∗ reg-
ulated apoptosis, cell proliferation,migration, and invasion in
OSCC cells [29]. These miR-31∗ regulated functional effects
were mediated by the regulation of fibroblast growth factor 3
(FGF3) [29] and RhoA [32] expression levels.
miR-146a has been demonstrated to be overexpressed
in OSCC and to enhance OSCC tumorigenesis both in the
in vitro and in vivo mouse xenograft model [33, 34]. The
oncogenic functions of miR-146a were found to be associated
with concomitant downregulation of IL-1 receptor-associated
kinase 1 (IRAK1), TNF receptor-associated factor 6 (TRAF6),
and NUMB [33]. A previous study from the same group
suggested an association between a higher OSCC miR-
146a expression and nodal involvement in patients carrying
C polymorphism (rs2910164) [34]. However, findings from
Palmieri et al. indicated that the rs2910164 polymorphism is
not associated with OSCC progression [35]. Further investi-
gations are needed to clarify a possible role of the variant allele
or rs2910164 in OSCC progression.
miR-134 expression was upregulated in HNSCC tissue
specimens and cells (HSC-3, OECM-1, and SAS cell-lines)
compared to the corresponding normal controls. Functional
analysis revealed thatmiR-134 expression enhanced the onco-
genicity of HNSCC cells in vitro as well as tumor growth and
metastasis of HNSCC cells in vivo via targetingWWdomain-
containing oxidoreductase (WWOX) [36]. In another study,
miR-155 was found to be overexpressed in OSCC cells and
tissues compared to the controls [37, 38]. Oncogenic effects
of miR-155 were suggested to be due to downregulation of
a tumor suppressor CDC73 in OSCC [39]. Similarly, miR-
27a was shown to downregulate expression of and to inhibit
tumor suppressor function of microcephalin 1 (MCPH1) in
OSCC cells [40].
4. miRNAs as Tumor Suppressors in OSCC
Several miRNAs have been shown to be downregulated in
OSCC. Accordingly, functional studies have demonstrated
tumor suppressive roles for these miRNAs in OSCC tumori-
genesis. miR-320 was downregulated in OSCC-derived cell-
lines and tissue specimens, with its expression correlating
inversely with the vascularity. Hypoxia suppressed miR-320
expression through HIF-1𝛼 and increased the expression of
neuropilin 1 (NRP1) and promoted the motility and tube
formation ability of endothelial cells via vascular endothelial
growth factor (VEGF) signaling pathway, resulting in tumor
angiogenesis [41].
The function of miR-7 has been characterized as a tumor
suppressor in several human cancers, including glioblas-
toma, breast cancer, and OSCC among others. A number
of protooncogenes were experimentally confirmed as its
target genes, including insulin receptor substrate 1 (IRS1),
insulin receptor substrate 2 (IRS2), epidermal growth factor
receptor (EGFR), v-raf-1 murine leukaemia viral oncogene
homologue 1 (RAF1), and p21/CDC42/RAC1-activated kinase
1 (PAK1) [42–44]. Jiang et al. showed that miR-7 regulated
IGF1R/IRS/PI3K/Akt signaling pathway by posttranscrip-
tional regulation of insulin-like growth factor 1 receptor
(IGF1R) in cells derived from tongue squamous cell carci-
noma (TSCC, the most common subtype of OSCC) cells
[45]. Similarly, studies have demonstrated that IGF1R and
mammalian target of rapamycin (mTOR), components of
IGF1R signaling pathway, are target genes of another tumor
suppressor miRNA, the miR-99a [46, 47]. Downregulation
of miR-99a was observed in OSCC patient specimens and
cell-lines [46, 47], especially in OSCC patients with lym-
phovascular invasion [46], suggesting a role for miR-99a
in lymphovascular invasion. In addition, miR-99a induced
apoptosis and inhibited OSCC cell proliferation, migration,
and invasion in vitro as well as lung colonization in vivo
[46, 47].
miR-218 has been shown to be epigenetically (DNA
hypermethylation) silenced in OSCC tissue specimens and
to have a tumor suppressive function by regulating the
expression of rapamycin-insensitive component of mTOR,
Rictor [48]. DNA hypermethylation has been suggested as
one of the mechanisms for the downregulation of miR-9
in OSCC and oropharyngeal carcinoma [49]. Lentivirus-
mediated miR-9 overexpression in highly aggressive tumor
cells led to significant inhibition of proliferation in vitro and
in vivo. These tumor suppressive functions were suggested
to be mediated via targeting CXC chemokine receptor 4
(CXCR4) gene and Wnt/𝛽-catenin signaling pathway [50].
Accumulating evidence suggests a critical role for EMT in
tumor progression, invasion, and metastasis and acquisition
of stem-like phenotype [51]. Findings from a number of
studies point towards a role of miRNAs in the regulation of
EMT and EMT-related malignant phenotypes in OSCC cells.
Different studies have shown a role for miR-138 in the sup-
pression of EMT, cell proliferation, migration, and invasion
inHNSCC-derived cells. At themolecular level, miR-138 reg-
ulated the expression of key EMT-related molecules like Fos-
like antigen 1 (FOSL1), vimentin (VIM), zinc finger E-box-
binding homeobox 2 (ZEB2), enhancer of zeste homologue
2 (EZH2), RhoC, and ROCK2 [52–54]. Furthermore, miR-
138 was suggested to suppress the expression of prometastatic
RhoC and other downstream signaling molecules FAK, Src,
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and Erk1/2 in HNSCC-derived cells [55]. Likewise, miR-
181a was shown to inhibit Twist1 mediated EMT, metastatic
potential and cisplatin induced chemoresistance in TSCC
cells [56].
Recent studies have shown that miRNAs play a crucial
role in the regulation of extracellular matrix (ECM) compo-
nents, such as matrix metalloproteinases (MMPs) and inte-
grins. Lu and coworkers reported that miR-29a was under-
expressed in OSCC tissues and inhibited the expression of
MMP2 by directly binding to the MMP2 3󸀠-UTR. Function-
ally, miR-29a inhibited invasion and antiapoptosis of OSCC-
derived cells [57]. Further functional studies revealed that
transfection with miRNA-29a mimics attenuated invasive
potential, increased apoptosis rate, and enhanced chemosen-
sitivity of OSCC cell-lines to cis-platinum (CDDP) [57].
miR-124 was found to be downregulated in OSCC and
its forced expression suppressed OSCC cell migration and
invasion through downregulation of ITGB1 expression [58].
Furthermore, miR-491-5p was shown to suppress invasion
and metastatic potential of OSCC cells in vitro and in vivo
by targeting the expression of G-protein-coupled receptor
kinase-interacting protein 1 (GIT1), which further regulated
the expression of focal adhesions, steady-state levels of pax-
illin, phospho-paxillin, phospho-FAK, EGF/EGFR-mediated
extracellular signal-regulated kinase (ERK1/2) activation, and
MMP2/9 levels and activities [59].
A miRNA cluster, miR-17-92, including miR-17, miR-
19b, miR-20a, and miR-92a, was found to be significantly
downregulated in a more migratory OSCC-derived TW2.6
MS-10 cells as compared to the less migratory TW2.6 cells.
Overexpression of this cluster was found to decrease the
migratory ability of OSCC cell-lines.Through a bioinformat-
ics screening analysis and 3󸀠-UTR reporter assay, integrin
(ITG) 𝛽8 was identified to be a direct target of miR-17/20a
in OSCC cells [60]. Likewise, miR-375 was shown to be
downregulated in HNSCC and to function as a tumor
suppressor by regulating the expression of AEG-1/MTDH,
CIP2A (cancerous inhibitor of protein phosphatase 2A).
Transient transfection of miR-375 in HNSCC-derived cells
reduced the expression of CIP2A (cancerous inhibitor of
protein phosphatase 2A) [61, 62]. Furthermore,miR375 sensi-
tized TNF-𝛼-induced apoptosis probably through inhibiting
NF-𝜅B activation in vitro [63]. Previous studies have sug-
gested miR-34a, which was frequently downregulated in a
number of tumor types, to function as a tumor suppressor.
Ectopic expression of miR-34a suppressed proliferation and
colony formation of HNSCC cells by downregulation of E2F
transcription factor 3 (E2F3) and survivin in the in vitro and
in vivo models [64]. miR-34a further led to the inhibition of
tumor angiogenesis by blocking VEGF production as well as
by directly inhibiting endothelial cell functions [64]. miR-
125b, another downregulated miRNA in OSCC, was able
to inhibit proliferation rate and to enhance radiosensitivity
to X-ray irradiation via downregulation of ICAM2 mRNA
expression in OSCC-derived cells [65]. Likewise, miR-145
was found to be frequently downregulated in OSCCs [66]
and to inhibit OSCC cell proliferation and colony formation
[67].
5. Diagnostic and Prognostic Value of
miRNAs in OSCC
Distinct expression profile of miRNA in OSCC and oral
prelalignant tissue specimens compared to the normal con-
trols offers the use of specific miRNA(s) signature for early
stage diagnosis and prediction of OSCC prognosis [16, 17].
In addition, miRNAs possess the following unique properties
whichmake them attractive diagnostic and prognostic tool in
OSCC. Firstly, they are abundantly expressed in OSCC and
control tissues and hence their isolation and quantification
are convenient and reproducible. Secondly, several OSCC-
related miRNAs are secreted in bodily fluids such as serum,
plasma, and saliva [68] making them very useful for nonin-
vasive clinical application. Candidate miRNAs reported to be
relevant forOSCCdiagnostics and prognosis are summarized
in Table 2.
5.1. miRNA as Diagnostic Biomarkers. The use of a specific
miRNA signature as a diagnostic tool in OSCC has been
suggested by a number of recent studies. miR-16 and let-7b
were highly upregulated in sera frompatients withOSCC and
oral carcinoma in situ, while miR-338-3p, miR-223, and miR-
29a were highly downregulated as compared to the matched
controls. ROC analysis indicated that the signature of five
miRNAs (miR-16, let-7b, miR-338-3p, miR-223, and miR-
29a) might be useful as a biomarker for oral cancer detection
(AUC > 0.8) [69]. Lin et al. showed that the plasma levels
of miR-24 in OSCC patients were significantly higher than
in the control individuals [70]. Likewise, the elevated plasma
levels of miR-21 and miR-146a were suggested to have a
diagnostic value in OSCC [33, 71]. Expression level of miR-
31 in saliva was found to be significantly increased in patients
with OSCC of all clinical stages as compared to that of the
healthy controls. The high salivary level was significantly
reduced after excision of OSCC lesion, indicating that the
main contributor for miR-31 upregulation was OSCC lesion
[72]. In addition, increased expression of miR-27b in saliva
of OSCC patients was suggested as a valuable biomarker
to identify OSCC patients by ROC curve analyses [73].
However, another study showed a downregulated expression
of miR-27b in both the tumor tissues and the plasma of
OSCC patients [74]. Further research is therefore required
to validate the above findings and elucidate the molecular
mechanismof different levels ofmiR-27b in saliva and plasma
in OSCC.
In addition to their potential use in OSCC diagnosis,
several miRNAs were suggested to be important in the earlier
diagnosis and prediction of malignant transformation of
oral premalignant lesions/conditions. Dang et al. showed
a significantly higher methylation frequency of miR-137
promotor in patients with oral lichen planus (35%) andOSCC
(58.3%) as compared to the absence of methylation in normal
controls, suggesting that the methylation status of miR-137
might be a valuable biomarker in the prediction of malignant
transformation of OLP [75]. In saliva, significantly different
expressions of miR-10b, miR-145, miR-99b, miR-708, and
miR-181c were observed in progressive low grade dysplasia
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Table 2: miRNA deregulation and relevance to OSCC diagnosis and prognosis.
miRNA(s) Source Up/downregulation (OSCCversus normal control) Diagnostic/prognostic relevance Ref.
miR-16, Let-7b Serum Up Yes/ND [69]a
miR-223, miR-29a, Serum Down
and miR-338-3p
miR-24 Plasma Up Yes/ND [70]
miR-146a Tissue/plasma Up Yes/ND [33]
miR-21
Tissue Up Yes/ND [71]b
Plasma Up Yes/yes
Tissue Up ND/yes [16]c
Tissue Up ND/yes [26]
Tissue Up Yes/yes [17, 80]b
Tissue Up ND/yes [20]d
miR-31 Saliva Up Yes/ND [72]
miR-27b Saliva Up Yes/ND [73]
miR-125b Tissue Down ND/yes [65]
miR-491-5p Tissue Down ND/yes [59]
miR-181 Plasma/tissue Up Yes/yes [77]
miR-375 Tissue Down ND/yes [78]b
miR-205 and Let-7d Tissue Down ND/yes [79]b
miR-155 Tissue Up ND/yes [38]
Tissue Up Yes/yes [37]
miR-21-3p Tissue Up ND/yes [97]
miR-141-3p
miR-96-5p
miR-130b-3p
miR-196a/b Tissue Up Yes/yes [98]
miR-196a Plasma Up Yes/yes
miR-211 Tissue Down ND/yes [99]
aOSCC group also consists of lesions with carcinoma in situ; bHNSCC specimens; cTSCC; dexpression examined in the tumor stroma; Ref.: references; ND:
not determined.
(LGD) as compared to nonprogressive LGD leukoplakia
patients [76].
5.2. miRNA as Prognostic Biomarkers. The expression pat-
terns of certain miRNAs have been found to correlate with
clinical stage, lymph node metastasis, and patient survival,
indicating that thesemiRNAs can act as prognostic predictors
in OSCC. Higher expression levels of miR-21 in TSCC corre-
lated with advanced clinical stage, poor differentiation, and
lymph node metastasis [16]. Moreover, multivariate analysis
showed that expression level of miR-21 could be used as an
independent prognostic factor for TSCC patients’ survival
[16]. Similarly, prognostic value of miR-21 in OSCC/HNSCC
was reported in another study [26]. miR-31, miR-17/20a,miR-
125b, miR-155, miR-181, miR-375 and miR-491-5p, miR-205,
and miR-let7d were found to be associated with lymph node
metastasis and poor OSCC patient survival [38, 59, 60, 65, 72,
77–80].
5.3. miRNA as Target for OSCC Therapy. The ability to
manipulate miRNAs expression and function by local and
systemic delivery ofmiRNA inhibitors (anti-miRNAoligonu-
cleotides or miRNA sponges [81, 82]) or miRNAmimics [82]
has recently gained immense interest as novel therapeutic
approach. This treatment approach came into light after the
first successful anti-miRNA oligonucleotides based human
clinical trial in 2011 for the treatment of hepatitis C virus
infection (reviewed in [83]). Recent identification of key
miRNAs with either oncogenic or tumor suppressive func-
tions in OSCC has opened up new possibilities for miRNA
based OSCC therapy. The advantage of miRNA based cancer
therapy lies in the ability of miRNAs to concurrently target
multiple effectors of pathways involved in cell proliferation,
differentiation, and survival [82]. Accordingly, several in
vitro and in vivo studies, employing strategies to suppress
the function of oncogenic miRNA and/or restore the tumor
suppressive miRNAs, have reported significant inhibition of
aggressiveOSCCphenotypes. For example, inhibitingmiR-21
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by anti-miRNA oligonucleotides has been shown to inhibit
survival, anchorage-independent growth [16], and invasion
[18] of OSCC cells. Likewise, restoration of miR-99a level by
miR mimic transfection markedly suppressed proliferation
and induced apoptosis of TSCC cells [47].
Resistance to chemotherapy and resistance to radio-
therapy are major challenges in the management of OSCC
patients as significantly high proportions of OSCC lesions fail
to respond to these treatment modalities. Recent studies have
linked resistance to chemotherapy and radiotherapy inOSCC
to altered miRNA expression and function. Dai et al. have
correlated a miRNA signature (downregulation of miR-100,
miR-130a, and miR-197 and upregulation of miR-181b, miR-
181d, miR-101, and miR-195) in HNSCC cells with multiple
drug resistance phenotypes in vitro [84]. In another study, low
expression ofmiR-200b andmiR-15b in TSCCwas associated
with chemotherapeutic resistance and poor patient prognosis
[85]. Similarly, higher expression ofmiR-196awas reported to
be associated with recurrent disease and resistance to radio-
therapy in HNSCC [86]. The miRNA signature(s) related to
therapeutic resistance has also been used experimentally to
revert the resistance phenotypes. For example, inhibition of
miR-21 by anti-miRNA oligonucleotides has been shown to
inhibit chemoresistance in OSCC cells [24, 87]. Likewise,
forced expression of miR-125b has been reported to enhance
radiosensitivity in OSCC cells [65]. Recently, nanoparticle
based delivery of miRNAs was suggested as a promising
approach in the treatment of HNSCC [88]. Despite these
promising results, more in-depth studies are necessary to
better understand the effective delivery system for optimal
uptake and to minimize degradation of miRNA based drugs
in the in vivo situation.
6. Conclusions
Alteration in the expression pattern of miRNA is a common
finding in OSCC tumorigenesis. Several altered miRNAs
seem to play critical roles in the initiation and progression of
OSCC by functioning either as oncogenes or as tumor sup-
pressors. Specific miRNA signatures identified from tumor
specimens, serum/plasma, or saliva from OSCC patients
have a potential to be clinically useful in the diagnosis,
prognosis, and therapeutic targets in OSCC. Nevertheless,
it will be a big challenge ahead to translate these promising
findings to clinic before the following issues will be fully
addressed. Firstly, findings from several studies are based on
limited number of patient materials from different subloca-
tions of oral cavity, which lead to more heterogeneous data
and reduced statistical power. Additionally, use of different
expression profiling platforms (such as microarray or PCR)
with different normalizing strategies leads to inconsistent
miRNA expression results. Hence, a comprehensive miRNA
profiling including larger number of paired tissue specimens
of oral premalignant lesions/conditions, primary OSCC, and
metastasis will enable us to identify miRNAs involved in
stepwise tumorigenesis and metastatic process of OSCC.
The identified miRNAs will pave the way for their future
clinical use in the diagnosis, prognosis and therapy of
OSCC.
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